Completed NA INTERVENTIONAL 4-arm NCT04715113

Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hypertension (HEXABM)

Hemodynamic Effects of Acute Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension: Single-center Randomized Controlled Trial

Sponsor: University of Zurich

Conditions Hypertension, Pulmonary

Interventions Normobaric hypoxia (FiO2 15%) Normobaric hypoxia (FiO2 15%) under Sildenafil Placebo-ambient air (FiO2 21%) Placebo-ambient air (FiO2 21%) under Sildenafil

Updated 6 times since 2021 Last updated: Jun 5, 2023 Started: Feb 1, 2021 Primary completion: May 31, 2023 Completion: May 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Hypertension, Pulmonary, this trial is completed. The trial is conducted by University of Zurich and has accumulated 6 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jul 2023 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed
Jun 2022 — Jul 2023 [monthly]

Recruiting NA
May 2021 — Jun 2022 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2021 — May 2021 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Zurich

Data source: University of Zurich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zurich, Switzerland